Exchange: NYSEArca·Updated 07:37 AM EDT

FBT News

News
all
press releases
ETFs That You May Consider Amid a Strengthening Biotech Outlook
Drug innovation, AI and rising M&A activity are boosting biotech optimism. Discover ETFs offering exposure to the sector.
Zacks
ETFs That You May Consider Amid a Strengthening Biotech Outlook
Drug innovation, AI and rising M&A activity are boosting biotech optimism. Discover ETFs offering exposure to the sector.
Zacks
More News
BNTX Stock Selloff Deepens Doubts: BMO Ties BNT113 Miss To Wider mRNA Cancer Vaccine Struggles
BMO Capital Markets analyst Evan David Seigerman said that the PFS miss for BNT113 “adds to a growing list of recent mRNA cancer vaccine setbacks” and is likely to pressure the stock.
Stocktwits
Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate
Biotech ETFs offer diversified exposure to oncology innovation as cancer funding surges and the global oncology drug market expands.
Zacks
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
Smart Beta ETF report for FBT
Zacks
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
Sector ETF report for FBT
Zacks
The Zacks Analyst Blog Highlights Amgen, Crinetics, FBT, BBH and BBP
Biotech ETFs are riding innovation, obesity drug growth and M&A, offering diversified exposure to the sector???s powerful rally.
Zacks
Bet on These Biotech ETFs as Innovation Drives Market-Beating Growth
Biotech ETFs are riding a powerful rally fueled by innovation, obesity drugs and M&A, with three funds offering diversified exposure to growth.
Zacks
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
Smart Beta ETF report for FBT
Zacks
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
Sector ETF report for FBT
Zacks
ONC Stock Gains As BeOne Medicines Wins US Nod For BEQALZI In Rare Lymphoma
The FDA approved BEQALZI in the treatment of certain mantle cell lymphoma patients on Wednesday.
Stocktwits

Advertisement|Remove ads.